GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » Forward Dividend Yield %

Intra-Cellular Therapies (BSP:I2TC34) Forward Dividend Yield % : 0.00% (As of Jun. 09, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies Forward Dividend Yield %?

As of today (2024-06-09), the Forward Annual Dividend Yield of Intra-Cellular Therapies is 0.00%.

As of today (2024-06-09), the Trailing Annual Dividend Yield of Intra-Cellular Therapies is 0.00%.

BSP:I2TC34's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.95
* Ranked among companies with meaningful Forward Dividend Yield % only.

Intra-Cellular Therapies's Dividends per Share for the three months ended in Mar. 2024 was R$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Intra-Cellular Therapies's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Forward Dividend Yield % falls into.



Intra-Cellular Therapies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Intra-Cellular Therapies  (BSP:I2TC34) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Intra-Cellular Therapies Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (BSP:I2TC34) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines